SCHEMBL30179205

SCHEMBL30179205

COCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCC(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 6/20 0.42
HSD17B10 Q99714 1/20 0.39
MGAM O43451 1/20 0.39
GAA P10253 1/20 0.39
SI P14410 1/20 0.39
MGAM2 Q2M2H8 1/20 0.39
CA2 P00918 1/20 0.35
NAMPT P43490 1/20 0.35
ABCB11 O95342 1/20 0.34
CYP3A4 P08684 1/20 0.34
ADRA2B P18089 1/20 0.34
OPRD1 P41143 1/20 0.34
SCN5A Q14524 1/20 0.34
EPHX2 P34913 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
TET2 Q6N021 1/20 0.32
ALDH1A1 P00352 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5049754 1.00 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL16917910 1.00 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL15360069 1.00 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL31672720 1.00 TSHR (0.42) TSHRHSD17B10MGAMGAASI
SCHEMBL518145 0.98 TSHR (0.43) TSHRHSD17B10MGAMGAASI
SCHEMBL7648165 0.93 TSHR (0.48) TSHRHSD17B10MGAMGAASI
SCHEMBL6463788 0.90 TSHR (0.50) TSHRHSD17B10MGAMGAASI
SCHEMBL28565203 0.86 CA2 (0.35) TSHRCA2NAMPTABCB11CYP3A4
SCHEMBL8390474 0.86 CA2 (0.35) TSHRCA2NAMPTABCB11CYP3A4
SCHEMBL14193699 0.85 MGAM (0.39) TSHRHSD17B10MGAMGAASI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES UNIV YALE (US) 2026-04-30 US disclosed
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES YALE UNIVERSITY 2023-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230000994-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, ARAF, VHL TSHR 2304/4885HSD17B10 3903/4885MGAM 3076/4885
US-20260115296-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES CRBN, VHL, ADRM1 TSHR 1899/4885HSD17B10 3249/4885MGAM 2468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.